Sun Pharmaceutical Industries Limited SUNPHARMA NIFTY50NSEAIPHARMA

Q: What is the current share price of Sun Pharmaceutical Industries Limited (SUNPHARMA)?

As of 2026-07-15 09:52 IST, Sun Pharmaceutical Industries Limited (SUNPHARMA) trades at ₹1,948.80 on NSE. Its 52-week range is ₹1,549.15 to ₹1,948.80.

Q: What is the market capitalisation of SUNPHARMA?

Sun Pharmaceutical Industries Limited (SUNPHARMA) has a market capitalisation of ₹4.68 L Cr on NSE.

Q: What is the P/E ratio of SUNPHARMA?

SUNPHARMA trades at a trailing price-to-earnings (P/E) ratio of 40.77. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.52.

Q: Does SUNPHARMA pay a dividend?

Sun Pharmaceutical Industries Limited (SUNPHARMA) currently offers a dividend yield of 0.83%.

Q: What is the return on equity (ROE) of SUNPHARMA?

SUNPHARMA has a return on equity (ROE) of 13.74%. Its return on capital employed (ROCE) is 17.94%.

Q: Is SUNPHARMA a good stock to buy?

This page provides a data-driven analysis of Sun Pharmaceutical Industries Limited (SUNPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://sunpharma.com

Company Profile ↓

₹1,948.80

+18.29% 1Y

Mkt Cap₹4.68 L Cr

P/E40.77

P/B5.52

Div. Yield0.83%

52W High₹1,948.80

52W Low₹1,549.15

Book Value₹348.31

EPS (TTM)₹47.80

Company Overview

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 17.9%.

Consistent Profit Growth

Net profit has compounded at 10.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 10.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 19.7%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹58,220.11 Cr (+11.9% YoY); net profit ₹11,479.42 Cr.
Trailing 12 Months Year-on-year growth — revenue +11.9%, earnings +5.0%.
5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 10.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	10.39%
1 Year:	11.87%

Compounded Profit Growth

5 Years:	10.65%
1 Year:	5.04%

Stock Price Performance

1 Year:	+18.29%
6 Months:	+13.28%
3 Months:	+16.62%
1 Month:	+8.51%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

AI Exposure AI Pharma / AI in Drug Discovery

Core Focus

Sun Pharma uses AI in drug discovery (collaborations with Atomwise, Schrödinger), AI for sales force productivity, and pharmacovigilance AI.

Key Initiatives

AI in specialty R&D Sun Pharma applies AI/ML to drug discovery, formulation and clinical workflows, especially across its growing specialty and innovation pipeline.
AI in manufacturing & quality Machine-learning process control and predictive quality across plants support compliance and yield.
Digital commercial & supply chain AI-driven analytics in sales and supply chain sharpen execution across global markets.

Why Investors Should Care

AI is a productivity lever on R&D and operations for India's largest pharma company.
Strong returns (ROCE ~21%) and ~38% five-year profit CAGR with a robust balance sheet.
Specialty pipeline gives growth optionality beyond generics.
Reasonable P/E ~35 for a high-quality, defensive compounder.

AI InvestmentR&D ~7% of revenue (~₹3,500 Cr); subset for AI/digital tools.

AI RevenueRevenue ~₹52,000 Cr FY25.

ROI (Now)EBITDA margin ~28%; ROE ~17%.

ROI (Expected)AI-driven specialty pipeline (Halol, R&D centres) expected to unlock value over 5-7 years.

Curated from public filings and analyst commentary; figures are illustrative.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 10.4% over 5 years.
Profit CAGR of 10.6% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

40.77

Industry PE

39.97

Forward P/E

30.13

PEG Ratio

1.04

Book Value

₹348.31

Price to Book

5.52

P/S

7.89

EV/EBITDA

26.51

Dividend Yield

0.83%

Growth (CAGR)

Revenue 5Y

10.39%

Profit 5Y

10.65%

Revenue (YoY)

11.87%

Earnings (YoY)

5.04%

Profitability & Returns

ROCE

17.94%

ROE

13.74%

ROA

10.55%

Profit Margin

19.72%

Op Margin

23.35%

Gross Margin

77.37%

EPS (Latest Qtr)

₹11.30

EPS (TTM)

₹47.80

Balance Sheet & Liquidity

Debt/Equity

0.06

Quick Ratio

2.32

Current Ratio

2.82

Debt

₹4,627.32 Cr

Total Assets

₹1.09 L Cr

Current Assets

₹63,891.19 Cr

Working Capital

₹41,269.15 Cr

Ownership

Promoter Holding

55.61%

Chg in Prom Hold

1.13%

FII / Inst Holding

28.82%

Chg in FII Hold

0.04%

Financial Snapshot

Enterprise Value

₹4.68 L Cr

Total Revenue (TTM)

₹58,220.11 Cr

EBITDA

₹18,395.64 Cr

Free Cash Flow

₹8,809.81 Cr

Operating Cash Flow

₹12,419.18 Cr

Shares Outstanding

₹239.93 Cr

Gross Margin

77.37%

Payout Ratio

34.52%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,948.80	40.77	₹4.68 L Cr	0.83%	17.94%	13.74%	10.39%	10.65%
2	DIVISLAB Divi's Laboratories Limited NSEPHARMA	7,315.50	75.61	₹1.94 L Cr	0.44%	18.96%	15.32%	11.27%	12.08%
3	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,952.20	87.70	₹1.68 L Cr	0.78%	9.05%	25.79%	13.27%	20.22%
4	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	8,981.00	66.51	₹1.29 L Cr	0.23%	19.79%	20.48%	15.33%	33.34%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,440.10	22.07	₹1.16 L Cr	0.90%	14.86%	11.27%	7.23%	11.45%
6	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,137.40	22.71	₹1.14 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
7	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,494.30	21.42	₹1.14 L Cr	0.72%	28.42%	23.76%	19.10%	131.46%
8	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	1,099.00	99.82	₹1.07 L Cr	0.18%	12.57%	13.42%	22.37%	9.34%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,562.00	55.36	₹1.06 L Cr	0.08%	13.75%	11.74%	17.73%	14.28%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	10,931.00 Cr	11,941.00 Cr	12,192.00 Cr	12,381.00 Cr	11,983.00 Cr	12,653.00 Cr	13,291.00 Cr	13,436.94 Cr	12,815.58 Cr	13,786.07 Cr	14,478.00 Cr	15,469.07 Cr	14,559.75 Cr
Cost of Revenue	-	-	-	-	-	-	-	2,740.54 Cr	2,637.19 Cr	2,814.76 Cr	-	2,945.10 Cr	2,801.09 Cr
Gross Profit	-	-	-	-	-	-	-	10,696.40 Cr	10,178.39 Cr	10,971.31 Cr	-	12,523.97 Cr	11,758.66 Cr
Operating Expenses	8,129.00 Cr	8,609.00 Cr	9,013.00 Cr	8,904.00 Cr	8,948.00 Cr	9,045.00 Cr	9,352.00 Cr	7,134.59 Cr	7,417.33 Cr	7,599.24 Cr	9,951.00 Cr	8,461.73 Cr	9,006.68 Cr
Operating Income	2,130.00 Cr	2,681.00 Cr	2,546.00 Cr	2,855.00 Cr	2,385.00 Cr	2,953.00 Cr	3,313.00 Cr	3,561.81 Cr	2,761.06 Cr	3,372.07 Cr	3,797.00 Cr	4,062.24 Cr	2,751.98 Cr
EBITDA	2,802.00 Cr	3,332.00 Cr	3,179.00 Cr	3,477.00 Cr	3,035.00 Cr	3,608.00 Cr	3,939.00 Cr	4,158.47 Cr	3,967.28 Cr	3,948.12 Cr	4,527.00 Cr	5,037.85 Cr	4,412.70 Cr
Interest Expense	93.00 Cr	81.00 Cr	49.00 Cr	35.00 Cr	74.00 Cr	62.00 Cr	69.00 Cr	51.51 Cr	49.14 Cr	74.80 Cr	100.00 Cr	78.36 Cr	85.89 Cr
Pretax Income	2,240.00 Cr	2,481.00 Cr	2,791.00 Cr	3,000.00 Cr	2,816.00 Cr	3,424.00 Cr	3,598.00 Cr	3,476.40 Cr	3,254.35 Cr	3,172.77 Cr	4,168.00 Cr	4,227.16 Cr	3,551.34 Cr
Tax Provision	224.00 Cr	471.39 Cr	390.74 Cr	420.00 Cr	140.80 Cr	547.84 Cr	575.68 Cr	558.86 Cr	1,093.71 Cr	870.15 Cr	1,042.00 Cr	826.07 Cr	827.67 Cr
Net Income	1,983.00 Cr	2,006.00 Cr	2,385.00 Cr	2,561.00 Cr	2,659.00 Cr	2,861.00 Cr	3,037.00 Cr	2,903.38 Cr	2,149.88 Cr	2,278.63 Cr	3,125.00 Cr	3,368.81 Cr	2,714.03 Cr
Diluted EPS	8.27	8.43	9.90	10.52	11.06	11.82	12.67	12.10	9.00	9.50	13.00	14.00	11.30

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	27,392.00 Cr	28,487.00 Cr	31,578.00 Cr	26,489.00 Cr	29,066.00 Cr	32,838.00 Cr	33,498.00 Cr	-	43,278.87 Cr	47,758.45 Cr	52,041.25 Cr	58,220.11 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	11,942.42 Cr	12,069.66 Cr	12,197.51 Cr	13,173.14 Cr
Gross Profit	-	-	-	-	-	-	-	-	31,336.45 Cr	35,688.79 Cr	39,843.74 Cr	45,046.97 Cr
Operating Expenses	19,498.00 Cr	20,313.00 Cr	21,476.00 Cr	20,858.00 Cr	22,689.00 Cr	25,855.00 Cr	25,028.00 Cr	-	22,059.09 Cr	25,220.76 Cr	27,262.54 Cr	31,452.15 Cr
Operating Income	6,699.00 Cr	7,136.00 Cr	8,837.00 Cr	4,131.00 Cr	4,624.00 Cr	4,930.00 Cr	6,390.00 Cr	-	9,277.36 Cr	10,468.03 Cr	12,581.20 Cr	13,594.82 Cr
EBITDA	7,894.00 Cr	8,174.00 Cr	10,102.00 Cr	5,631.00 Cr	6,377.00 Cr	6,983.00 Cr	8,470.00 Cr	-	12,110.86 Cr	13,883.15 Cr	16,558.88 Cr	18,395.64 Cr
Interest Expense	579.00 Cr	523.00 Cr	400.00 Cr	518.00 Cr	555.00 Cr	303.00 Cr	141.00 Cr	-	172.00 Cr	238.47 Cr	231.36 Cr	338.91 Cr
Pretax Income	6,403.00 Cr	6,571.00 Cr	9,048.00 Cr	3,479.00 Cr	3,810.00 Cr	5,010.00 Cr	2,799.00 Cr	-	9,408.43 Cr	11,087.89 Cr	13,752.13 Cr	15,118.88 Cr
Tax Provision	896.42 Cr	919.94 Cr	1,176.24 Cr	904.54 Cr	609.60 Cr	801.60 Cr	503.82 Cr	-	847.59 Cr	1,439.45 Cr	2,772.03 Cr	3,554.36 Cr
Net Income	5,476.00 Cr	5,658.00 Cr	7,846.00 Cr	2,542.00 Cr	3,208.00 Cr	4,172.00 Cr	2,272.00 Cr	-	8,473.58 Cr	9,576.38 Cr	10,929.04 Cr	11,479.42 Cr
Diluted EPS	21.92	18.89	29.03	8.73	11.11	15.69	12.10	-	35.30	39.90	45.60	47.80

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	48,723.00 Cr	55,428.00 Cr	61,095.00 Cr	64,297.00 Cr	64,590.00 Cr	68,194.00 Cr	67,622.00 Cr	-	80,743.59 Cr	85,499.65 Cr	92,100.58 Cr	1.09 L Cr
Current Assets	-	-	-	-	-	-	-	-	39,883.34 Cr	43,474.98 Cr	52,624.47 Cr	63,891.19 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	4,623.73 Cr	9,285.65 Cr	10,268.77 Cr	9,770.51 Cr
Inventory	-	-	-	-	-	-	-	-	10,513.05 Cr	9,868.29 Cr	10,243.33 Cr	11,492.93 Cr
Receivables	-	-	-	-	-	-	-	-	11,438.51 Cr	11,249.37 Cr	13,046.11 Cr	15,509.67 Cr
Total Liabilities	-	-	-	-	-	-	-	-	21,428.12 Cr	18,373.71 Cr	19,614.63 Cr	24,905.48 Cr
Current Liabilities	-	-	-	-	-	-	-	-	19,907.00 Cr	16,984.40 Cr	18,194.21 Cr	22,622.04 Cr
Long Term Debt	-	-	-	-	-	-	-	-	0	1.33 Cr	2.52 Cr	31.26 Cr
Total Debt	8,996.00 Cr	8,497.00 Cr	9,832.00 Cr	10,385.00 Cr	10,514.00 Cr	8,315.00 Cr	3,869.00 Cr	-	6,885.87 Cr	3,273.67 Cr	2,362.19 Cr	4,627.32 Cr
Total Equity	25,638.00 Cr	32,983.00 Cr	36,640.00 Cr	38,314.00 Cr	41,409.00 Cr	45,265.00 Cr	46,463.00 Cr	-	55,995.38 Cr	63,666.75 Cr	72,218.02 Cr	83,570.09 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	5,616.00 Cr	6,686.00 Cr	7,082.00 Cr	3,907.00 Cr	2,196.00 Cr	6,555.00 Cr	6,170.00 Cr	8,985.00 Cr	4,959.33 Cr	12,134.98 Cr	14,072.09 Cr	12,419.18 Cr
Investing Cash Flow	-1,502.00 Cr	-3,949.00 Cr	-4,186.00 Cr	-3,104.00 Cr	-310.00 Cr	-2,225.00 Cr	407.00 Cr	-5,556.00 Cr	-7,943.68 Cr	-690.20 Cr	-5,306.16 Cr	-11,344.05 Cr
Financing Cash Flow	-1,187.00 Cr	-1,889.00 Cr	-2,285.00 Cr	-1,539.00 Cr	-2,731.00 Cr	-5,715.00 Cr	-5,980.00 Cr	-5,193.00 Cr	2,376.07 Cr	-6,710.16 Cr	-7,905.82 Cr	-2,512.55 Cr
Capital Expenditure	-2,300.00 Cr	-3,333.00 Cr	-3,590.00 Cr	-1,894.00 Cr	-3,162.00 Cr	-1,450.00 Cr	-1,073.00 Cr	-1,435.00 Cr	-2,085.58 Cr	-2,201.81 Cr	-2,128.58 Cr	-3,609.37 Cr
Free Cash Flow	3,316.00 Cr	3,353.00 Cr	3,492.00 Cr	2,013.00 Cr	-966.00 Cr	5,105.00 Cr	5,097.00 Cr	7,550.00 Cr	2,873.75 Cr	9,933.17 Cr	11,943.51 Cr	8,809.81 Cr
Net Change in Cash	2,927.00 Cr	848.00 Cr	611.00 Cr	-736.00 Cr	-844.00 Cr	-1,386.00 Cr	596.00 Cr	-1,765.00 Cr	-608.28 Cr	4,734.62 Cr	860.11 Cr	-1,437.42 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	72.4%	74.7%	76.6%	77.4%
Operating Margin %	24.5%	25.1%	28.0%	15.6%	15.9%	15.0%	19.1%	-	21.4%	21.9%	24.2%	23.4%
Net Margin %	20.0%	19.9%	24.8%	9.6%	11.0%	12.7%	6.8%	-	19.6%	20.1%	21.0%	19.7%
ROE %	21.4%	17.2%	21.4%	6.6%	7.7%	9.2%	4.9%	-	15.1%	15.0%	15.1%	13.7%
ROCE %	-	-	-	-	-	-	-	-	15.2%	15.3%	17.0%	15.8%

Shareholding Pattern

Insiders

55.61%

Institutions

28.82%

Public Float

64.93%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUNPHARMA

Google News Sun, 26 Apr 2026

Sun Pharma shares jump 7% as India's largest drugmaker to buy U.S. firm Organon in $11.75 billion deal - CNBC

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOOWZQamxKeFFmTU9MYmxhYU5YYVhDSHNBWjhJcHpEamFkVzdtVEpMeGM5emtudWhuWHhxTWxwbmF1aGVYM3lKOEwzbXpiRTU3RlBoNVdLVU9CYUFreFBXSzNOWVNxQ2paU0pTbDdWVnYxd2hmdkFBamlJRXJ2dUJZcEpfeFhpbzNGMTR0Rk…

Google News Wed, 15 Jul 2026

Trade Spotlight: How should you trade Sun Pharma, Balrampur Chini Mills, Blue Star, Caplin Point Labs,... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMipgJBVV95cUxOaHlNal9DeXlMMklSVUpGTGt0NXlwWmxNem12bHE4THNfRDdVX1VET05KcThhTzIta0dLVndPclphNm5vSVBpV216WWQwU29WcXFCX1lrZl85VFJTd2tfanliWk11NjRkUDIxcFhxM0lRZGVnbDZHQUh6WmRscTAzbjY0NVZad2JUZll2Qk…

Google News Wed, 15 Jul 2026

Sun Pharma gets South Africa approval for generic semaglutide - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPcjJGc29VZmVBd2pHOHVqbm5tT3Y0bEdGdVROZ3NhaDNHTUszRWpFbHl6QV9sYTZpNkl0dmFzd1BQSWF4UlpuNDJhdm1SeXREdUxKUnRUTmhDQ3l6bDJaM2lmd3ViQ3FmU2xvZlhvTDNfRzlUN04tdUJTNi1uRUZpU2R6VzdPMU80czNzOG…

Google News Mon, 27 Apr 2026

Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNQTJKTXJocHZEUTI2WVVsb0RlQnN6NnRyOExJU2c3OTgtYlpZMkxMTE1fRk1YODJ1b3NLU2JJbHctVmdFUmZBZy1sUFBmVHVnQ1JscmdMZXRSdWZIbUhhM1NFbjJuZzVXOTY4ZVd1TG9mOTgwV0RQdWV6MVNkS2lxaXR3MzJLMC1PVGZHOE…

Google News Mon, 27 Apr 2026

Sun Pharma shares rise 9% after $11.75B Organon acquisition confirmed - The Pharma Letter

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcVZPTnNtUjJmUktuLUZtZEdOTWlZejc2NHJ3Z0lNRVVYX0JPaFpZVi14RDUxeGpuQm5JVjQ0NmRxN0dsb0tkRGhPcmtSVTNxY0pFUWxtcEs0bGozUXhPWXRKN04tdENQSjh1UWRnYkR1QWJpdlZpcHFBaW9FZjNTbEF3bm8tVzU3UHNlMT…

Google News Sun, 26 Apr 2026

Sun Pharma signs Definitive Agreement to Acquire Organon - Business Wire

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNbnpXMXVJOEphZXFINWNRaVdfcDFWU25Wb1FmWEcxNWNtM2dUVkM2WXdFY1lMNUl0ZWhPV01sc05vc2ZydzVsbFl5OWlpa2lBT2wxemt4ZndRQ0k0cFVmNUhqQzc0UEwwbjhFVU92YnQ0bVdvQ0lwM1ZrdHNlTWowRE9MeHpFWEVSWXN0WV…

SUNPHARMA — Frequently Asked Questions

What is the current share price of Sun Pharmaceutical Industries Limited (SUNPHARMA)?

As of 2026-07-15 09:52 IST, Sun Pharmaceutical Industries Limited (SUNPHARMA) trades at ₹1,948.80 on NSE. Its 52-week range is ₹1,549.15 to ₹1,948.80.

What is the market capitalisation of SUNPHARMA?

Sun Pharmaceutical Industries Limited (SUNPHARMA) has a market capitalisation of ₹4.68 L Cr on NSE.

What is the P/E ratio of SUNPHARMA?

SUNPHARMA trades at a trailing price-to-earnings (P/E) ratio of 40.77. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.52.

Does SUNPHARMA pay a dividend?

Sun Pharmaceutical Industries Limited (SUNPHARMA) currently offers a dividend yield of 0.83%.

What is the return on equity (ROE) of SUNPHARMA?

SUNPHARMA has a return on equity (ROE) of 13.74%. Its return on capital employed (ROCE) is 17.94%.

Is SUNPHARMA a good stock to buy?

This page provides a data-driven analysis of Sun Pharmaceutical Industries Limited (SUNPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

Sun Pharmaceutical Industries Limited SUNPHARMA NIFTY50NSEAIPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

Sun Pharma shares jump 7% as India's largest drugmaker to buy U.S. firm Organon in $11.75 billion deal - CNBC

Trade Spotlight: How should you trade Sun Pharma, Balrampur Chini Mills, Blue Star, Caplin Point Labs,... - Moneycontrol.com

Sun Pharma gets South Africa approval for generic semaglutide - scanx.trade

Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout - Yahoo Finance

Sun Pharma shares rise 9% after $11.75B Organon acquisition confirmed - The Pharma Letter

Sun Pharma signs Definitive Agreement to Acquire Organon - Business Wire

SUNPHARMA — Frequently Asked Questions

What is the current share price of Sun Pharmaceutical Industries Limited (SUNPHARMA)?

What is the market capitalisation of SUNPHARMA?

What is the P/E ratio of SUNPHARMA?

Does SUNPHARMA pay a dividend?

What is the return on equity (ROE) of SUNPHARMA?

Is SUNPHARMA a good stock to buy?

Explore More